BPC-157 and TB-500 quality — sequence verification and the lyophilization question

BPC-157 and TB-500 quality verification has its own specific considerations. Both compounds are smaller than GLP-1 peptides and structurally simpler, but the quality issues in this category are different — sequence-incorrect product is more common, and stability handling matters more than for many other peptide classes. This thread covers what to look for on a COA specifically for these two compounds.

The basics still apply.
The general COA-reading skills covered in the COA & Lab Results category apply here. HPLC purity, mass spectrometry confirmation of identity, named accredited third-party lab, specific batch number matching the vial. If those basics are not present, do not buy regardless of category. This thread covers the additional considerations specific to BPC-157 and TB-500.

Acceptable purity thresholds.
For research-grade BPC-157 and TB-500, HPLC purity above 97% is the minimum acceptable threshold. Above 98% is good. Above 99% is excellent. These compounds are smaller than the GLP-1 class so synthesis cleanness is generally easier to achieve, and the higher-quality vendors in this space typically deliver 99%+ consistently.

Mass spectrometry expectations.

BPC-157: theoretical molecular weight 1419.53 Da (15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val).

TB-500: theoretical molecular weight 887.99 Da for the standard 7-amino-acid research fragment (the active region of thymosin beta-4: Leu-Lys-Lys-Thr-Glu-Thr-Gln). Note that some products labeled "TB-500" actually contain the full 43-amino-acid thymosin beta-4 (Tb4) molecule, which has a theoretical molecular weight of approximately 4963 Da. This is not necessarily a problem — Tb4 is the parent molecule and contains the active fragment — but the buyer should know which they are receiving and the dosing implications differ.

The mass spec value on the COA must match the theoretical weight for the compound. Sequence-incorrect synthesis is the most common quality issue in this category, and mass spec is the only reliable way to catch it from documentation alone.

The sequence verification question.
This is the BPC-157-specific quality concern that does not affect most other peptide classes. The published BPC-157 sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Synthesis errors that produce sequences with one or two amino acid swaps or omissions can still test as "approximately 1400 Da" on coarse mass spec but produce a molecule with substantially different biological activity. High-precision mass spec with sequence-confirming peaks (or amino acid analysis) is the more thorough verification.

A vendor providing only HPLC purity and a coarse molecular weight is providing the bare minimum. A vendor providing HPLC purity, precise mass spec confirmation, and amino acid analysis is providing high-confidence documentation that the product is actually BPC-157 with the correct sequence.

The TB-500 versus full thymosin beta-4 question.
Some vendors market "TB-500" that is actually the full thymosin beta-4 molecule (43 amino acids). Other vendors market "TB-500" that is the 7-amino-acid active fragment. Both are biologically active but the dosing differs by roughly an order of magnitude — full Tb4 is dosed at ~5x the mg amount of the fragment to deliver equivalent active material because most of the molecular weight is structural rather than active.

The COA mass spec catches this trivially. 887.99 Da is the fragment. ~4963 Da is the full molecule. A vendor selling a product labeled "TB-500" without disclosing which they are providing is creating dosing confusion that affects research outcomes.

The lyophilization question.
Both BPC-157 and TB-500 are typically supplied as lyophilized (freeze-dried) powder. Lyophilization is the standard form for research peptides and provides good stability when stored properly. The quality consideration here is whether the lyophilization was done correctly — improperly lyophilized product can have residual moisture content that accelerates degradation, and improperly stored lyophilized product can degrade through other pathways.

Quality indicators for lyophilization include: appearance description on the COA matches "white to off-white lyophilized powder" (not "yellow," "brown," or "discolored"); residual moisture content reported (should be less than 5%); product freezes and thaws cleanly without oily appearance.

Stability after reconstitution.
Both compounds are studied at various concentrations after reconstitution with bacteriostatic water (or sterile water for short-term use). Once reconstituted, refrigeration is standard and the typical research handling assumes use within 30 days for BPC-157 and 30-45 days for TB-500. Vendors making longer-stability claims (especially without supporting data) should be approached skeptically — the published stability research on reconstituted product does not extend to many of the marketing claims.

The "stable" or "arginate" BPC-157 marketing.
Some vendors sell BPC-157 in arginate salt form (rather than the standard acetate) and claim improved stability. The published comparative research on this is limited. The arginate version may have legitimate advantages but the marketing claims often outrun the data. If a vendor is selling arginate BPC-157 at a premium, ask for the comparative stability data they are basing the claim on. If they cannot provide it, the premium is for marketing rather than for measurably better product.

Endotoxin testing.
For injectable research, endotoxin levels should be reported with a value below the standard threshold (less than 5 EU/mg). Both compounds are typically used in subcutaneous injection volumes well under 1 mL, so even at modest concentrations the per-dose endotoxin exposure is far below pyrogenic thresholds. The presence of endotoxin testing on the COA signals overall vendor quality more than it represents a specific safety concern.

What a strong BPC-157 or TB-500 COA looks like in practice.
Specific batch number matching the vial. HPLC purity above 97% with chromatogram showing one dominant peak. Mass spectrometry confirming the theoretical molecular weight (with explicit clarity on whether TB-500 is the fragment or full Tb4). Amino acid analysis confirming sequence (especially for BPC-157). Residual moisture content reported and within acceptable range. Endotoxin testing below threshold. Named accredited third-party lab with verifiable report number.

If you are evaluating a vendor for either compound, request the COA before ordering and verify the mass spec matches the expected molecular weight for the labeled compound. Post questions or specific COAs in the Quality and COA discussion threads if you want a second pair of eyes.